15 / 34
Final Investigator-Assessed PFS, ORR and DOR
15
5.2 mo
(95% CI: 4.3, 5.6)
7.6 mo
(95% CI: 6.6, 8.5)
HR 0.60 (95% CI: 0.49, 0.72)
P
< 0.0001
Minimum follow-up, 11.7 mo
Median follow-up, 14.8 mo
Platin/Pem + Atezo in Non-SCC NSCLC
Impower 132 Trial
13.6 mo
(95% CI:
11.4, 15.5)
18.1 mo
(95% CI:
13.0, NE)
HR: 0.81 (95% CI: 0.64,
1.03)
P
= 0.0797
Minimum follow-up: 11.7 mo
Median follow-up: 14.8 mo
VA Papadimitrakopoulou et al. WLCC 2018